Boehringer’s Home-Grown IL-23 Inhibitor Outperforms Stelara
Executive Summary
Success of Boehringer’s BI 655066 in Phase II against Stelara bodes well for specific inhibition of IL-23.
You may also be interested in...
After The Anti-TNFs, What’s Next In Autoimmune Disease?
With the threat of biosimilars looming closer, the leaders in autoimmune disease are scrambling to bring novel drugs to market and extend their dominance beyond the anti-TNF class. But toppling the anti-TNFs’ reign won’t be easy, especially if cheaper biosimilar copies reach the market.
Rare Disease Roundtable: Dealing With Pricing Pressure
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.
Rare Disease Roundtable: How Rare Is Too Rare?
Part 1: Execs from rare disease-focused companies weighed in on investor sentiment during a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference.